Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

FENC - Fennec Pharmaceuticals Inc. So'nggi... | Finranks

Home

/

FENC

F

Fennec Pharmaceuticals Inc. (FENC)

NCM – Real vaqt narxi. Valyuta: USD

12.03

-0.75 (-5.87%)

Bozor ochiq: Aug 12, 2026, 11:31 AM EDT

12.40

-0.38 (-2.95%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Adherex Technologies Q2 Earnings Call Highlights

Adherex Technologies Q2 Earnings Call Highlights

Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Videolar

No Data

There is no data to display